glp 1 agonists names GLP-1 receptor and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits Glucagon-like peptide-1 receptor agonists (GLP-1RAs)

This study provides the basis for future screening studies to verify if animals have been exposed to toxicologic insults

In a promising advance for diabetes care, researchers at National Taiwan University (NTU) are exploring the potential of GLP-1 receptor agonists (GLP-1 RAs) to slow the progression of kidney disease and reduce mortality among diabetic patients with acute kidney conditions

After spending a whole night designing

Key points: In clinical trials, tirzepatide (Mounjaro) produced roughly double the average weight loss of liraglutide (Saxenda), though these were separate trials with different durations Tirzepatide at the 15 mg dose produced approximately 21% average weight loss over 72 weeks Liraglutide 3.0 mg produced approximately 8% average weight loss over 56 weeks Real-world data from Second Nature shows even greater results (22.1%) when tirzepatide is combined with behavioural support Side effects and tolerability Both medications share a similar side-effect profile, predominantly affecting the gastrointestinal tract